RESUMEN
Among 197 COVID-19 patients hospitalized in ICU, 88 (44.7%) experienced at least one bacterial infection, with pneumonia (39.1%) and bloodstream infections (15,7%) being the most frequent. Unusual findings include frequent suspicion of bacterial translocations originating from the digestive tract as well as bacterial persistence in the lungs despite adequate therapy.
Asunto(s)
Infecciones Bacterianas/complicaciones , COVID-19/complicaciones , Neumonía Bacteriana/complicaciones , Anciano , Infecciones Bacterianas/epidemiología , COVID-19/epidemiología , Femenino , Francia/epidemiología , Hospitalización , Humanos , Unidades de Cuidados Intensivos , Pulmón/microbiología , Pulmón/virología , Masculino , Persona de Mediana Edad , Neumonía Bacteriana/epidemiologíaRESUMEN
Because the diagnosis of co/superinfection in COVID-19 patients is challenging, empirical antibiotic therapy is frequently initiated until microbiological analysis results. We evaluated the performance and the impact of the BioFire® FilmArray® Pneumonia plus Panel on 112 respiratory samples from 67 COVID-19 ICU patients suspected of co/superinfections. Globally, the sensitivity and specificity of the test were 89.3% and 99.1%, respectively. Positive tests led to antibiotic initiation or adaptation in 15% of episodes and de-escalation in 4%. When negative, 28% of episodes remained antibiotic-free (14% no initiation, 14% withdrawal). Rapid multiplex PCRs can help to improve antibiotic stewardship by administering appropriate antibiotics earlier and avoiding unnecessary prescriptions.